| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:50 | SOD SCIENCES INC.: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test | 271 | ACCESS Newswire | Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic-disease patients VERO BEACH, FL / ACCESS Newswire... ► Artikel lesen | |
| Mo | Vivos Therapeutics acquires stake in SOD Sciences | 1 | Investing.com | ||
| Mo | Vivos Therapeutics erwirbt Beteiligung an SOD Sciences | 1 | Investing.com Deutsch | ||
| Mo | Vivos Therapeutics, Inc: Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel | 1 | GlobeNewswire (USA) | ||
| Do | Vivos Therapeutics to acquire minority stake in SOD Sciences in $12M stock transaction | 2 | Seeking Alpha | ||
| Do | Vivos Therapeutics, Inc: Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test | 1 | GlobeNewswire (USA) | ||
| VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Vivos Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 01.10. | Vivos Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.09. | Vivos Therapeutics plant jährliche Kostensenkungen von 3,6 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 29.09. | Vivos Therapeutics, Inc: Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives | 244 | GlobeNewswire (Europe) | LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and... ► Artikel lesen | |
| 01.09. | Vivos Therapeutics, Inc.: Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference | 827 | Newsfile | Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on... ► Artikel lesen | |
| 28.08. | Vivos Therapeutics, Inc: Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center | 6 | GlobeNewswire (USA) | ||
| 25.08. | Vivos Therapeutics, Inc: Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers | 1 | GlobeNewswire (USA) | ||
| 21.08. | Vivos Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.08. | Vivos Therapeutics opens Henderson facility with $10M capacity | 1 | Investing.com | ||
| 20.08. | Vivos Therapeutics, Inc: Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment | 1 | GlobeNewswire (USA) | ||
| 18.08. | Vivos Therapeutics: Service Revenue Nearly Doubles To $3.8 Million While Product Revenue Falls 28% | 4 | pulse2.com | ||
| 17.08. | Vivos Therapeutics GAAP EPS of -$0.31 misses by $0.01, revenue of $5.15M misses by $0.99M | 1 | Seeking Alpha | ||
| 15.08. | Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| 14.08. | Vivos Therapeutics steigert Umsatz im zweiten Quartal 2026 um 35 % | 1 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 12,860 | -0,46 % | Eckert & Ziegler: Independence gains value: Recent radiopharma transactions highlight the strategic value of EUZ's independent ... | Recent radiopharma acquisitions underline the value of EUZ's core capabilities: independent isotope supply and specialist manufacturing. Strategic and financial investors are acquiring comparable isotope... ► Artikel lesen | |
| TELADOC HEALTH | 5,554 | +8,56 % | Teladoc Health, Inc.: Teladoc Health to Announce Third Quarter 2026 Financial Results | ||
| SERNOVA BIOTHERAPEUTICS | 0,075 | +5,34 % | Sernova Biotherapeutics bekommt nur eine 4-: Warum unsere Experten so kritisch sind - Handeln Sie noch vor Börsenschluss! | ||
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics
07.09.2026 / 09:31 CET/CEST
The... ► Artikel lesen | |
| CERENOME | 1,370 | -4,86 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | NuGen Medical Devices Inc.: NuGen Announces Loan Agreement with Sol-Millennium Medical HK Limited | Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce the entering into of a loan agreement (the "Loan Agreement")... ► Artikel lesen | |
| CARDINAL HEALTH | 227,40 | +0,93 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,300 | 0,00 % | Atossa Therapeutics: Stammaktien handeln ab sofort gekoppelt mit Contingent Value Rights | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| FRESENIUS | 45,000 | +0,21 % | EQS-News: Fresenius SE & Co. KGaA: Aufsichtsrat beruft Dr. Marc-Alexander Mahl in den Vorstand und verlängert Vertrag von Sara Hennicken | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Personalie
Aufsichtsrat beruft Dr. Marc-Alexander Mahl in den Vorstand und verlängert Vertrag von Sara Hennicken (News mit Zusatzmaterial)
15.10.2026... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,440 | +1,00 % | Siemens Healthineers sortiert sein Geschäft neu | Siemens Healthineers setzt einen ungewöhnlich klaren Schnitt im Ultraschallgeschäft. Statt weiterhin möglichst viele medizinische Anwendungen abzudecken, konzentriert sich der Konzern künftig stärker... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,950 | -2,79 % | Fresenius Medical Care AG: Kurzfristige Gegenwinde zunehmend eingepreist; Hochstufung auf KAUFEN | Fresenius Medical Care (FME) hat die Prognose für das Geschäftsjahr 2026 bestätigt, wobei auslaufende TDAPA-Effekte, schwache Behandlungsvolumina in den USA und Restrukturierungsaufwendungen das Ergebnis... ► Artikel lesen | |
| HEARTFLOW | 55,17 | +8,13 % | Piper Sandler raises HeartFlow stock price target on competitive moat | ||
| GERRESHEIMER | 32,760 | +0,12 % | EQS-News: Gerresheimer AG: Gerresheimer steigert EcoVadis-Ratingergebnis und wird erneut mit Gold ausgezeichnet | EQS-News: Gerresheimer AG
/ Schlagwort(e): Nachhaltigkeit/ESG
Gerresheimer steigert EcoVadis-Ratingergebnis und wird erneut mit Gold ausgezeichnet
14.10.2026 / 10:00 CET/CEST
Für... ► Artikel lesen |